Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MustGrow BiologicsMGROF 27 Equity-to-Asset is 0.71 as of Jun. 2026, which is 13% above its 10-year median of 0.63. GuruFocus rates MGROF with a GF Score™ of 27/100 and a GF Value™ of $0.60 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 261 Agriculture companies, MustGrow Biologics ranks better than 79.69% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. MustGrow Biologics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $3.60 Mil. MustGrow Biologics's Total Assets for the quarter that ended in Jun. 2026 was $5.10 Mil.
Therefore, MustGrow Biologics's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.71.
The historical rank and industry rank for MustGrow Biologics's Equity-to-Asset or its related term are showing as below:
MGROF'
s Equity-to-Asset Range Over the Past 10 Years
Min: -75.31 Med: 0.63 Max: 0.87
Current: 0.71
During the past 10 years, the highest Equity to Asset Ratio of MustGrow Biologics was 0.87. The lowest was -75.31. And the median was 0.63.
MGROF's Equity-to-Asset is ranked better than 79.69% of 261
companies
in the Agriculture industry
Industry Median: 0.53
vs MGROF: 0.71
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
MustGrow Biologics Equity-to-Asset Related Terms
MustGrow Biologics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for MustGrow Biologics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MGROF vs CTVA, CF, MOS: Equity-to-Asset Comparison
For the Agricultural Inputs subindustry, MustGrow Biologics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MustGrow Biologics Equity-to-Asset vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, MustGrow Biologics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where MustGrow Biologics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
MustGrow Biologics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MustGrow Biologics (MGROF) has a Equity-to-Asset of 0.71 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on MustGrow Biologics and its competitors. This is 13% above median its historical median of 0.63. According to the industry distribution chart, MustGrow Biologics ranks #53 out of 261 companies in the Agriculture industry, placing it in the top 20.3%.
Is MustGrow Biologics' Equity-to-Asset too high?
MustGrow Biologics' current Equity-to-Asset of 0.71 is 13% above median its 10-year median of 0.63. The Agriculture industry median Equity-to-Asset is 0.53. MustGrow Biologics' value of 0.71 is 34% above this industry median. Based on the distribution chart, MustGrow Biologics ranks #53 out of 261 companies in the Agriculture industry, which is in the top quartile — a strong position relative to peers. Overall, MustGrow Biologics has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MustGrow Biologics' Equity-to-Asset compare to CTVA and CF?
According to the Agriculture industry distribution chart, MustGrow Biologics ranks #53 out of 261 companies for Equity-to-Asset. This places MustGrow Biologics in the top 20% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.53. MustGrow Biologics' value of 0.71 is 34% above this benchmark. While the company's 10-year median is 0.63 vs. the industry median of 0.53, MustGrow Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for an Agriculture company?
The median Equity-to-Asset among Agriculture companies is 0.53, based on 261 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MustGrow Biologics's current Equity-to-Asset of 0.71 is 34% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on MustGrow Biologics and its competitors. For the Agriculture industry, the median Equity-to-Asset is 0.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MustGrow Biologics's current Equity-to-Asset is 0.71, which is 13% above median its own 10-year median of 0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MustGrow Biologics stock overvalued right now?
Based on GuruFocus' analysis, MustGrow Biologics (MGROF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.60, compared to a current price of $0.32 — trading 46.7% below its estimated fair value. The current Equity-to-Asset is 0.71, which is 13% above median its 10-year median of 0.63 and 34% above the Agriculture industry median of 0.53. MustGrow Biologics' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For MustGrow Biologics (MGROF), the current Equity-to-Asset is 0.71 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MustGrow Biologics (MGROF) Overvalued in 2026?
Based on GuruFocus' analysis, MustGrow Biologics stock appears to be undervalued.
The current stock price of $0.32 is trading 46.7% below its estimated GF Value™ of $0.60.
GuruFocus considers MustGrow Biologics to be Possible Value Trap.
Key valuation signals for MGROF:
Equity-to-Asset: 0.71 (13% above median its 10-year median of 0.63)
GF Value™: $0.60 vs. price of $0.32 (46.7% below fair value)
Industry Position: 34% above the Agriculture median (#53 of 261)
No single metric tells the full story. See the MGROF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MustGrow Biologics Corp is a fully integrated provider of biological and regenerative agriculture solutions designed to support sustainable farming. The Company's proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers. It offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, and foliar products. These products are synergistically distributed alongside MustGrow's wholly owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers.
27GF Score
Get the complete analysis for MGROF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MGROF has been successfully added to your 
